Open Access

Clinical characteristics and therapeutic outcomes of nosocomial super-infection in adult bacterial meningitis

  • Chi-Ren Huang1,
  • Shu-Fang Chen1, 2,
  • Cheng-Hsien Lu1,
  • Yao-Chung Chuang1,
  • Nai-Wen Tsai1,
  • Chiung-Chih Chang1, 2,
  • Hung-Chen Wang3,
  • Chun-Chih Chien4 and
  • Wen-Neng Chang1Email author
BMC Infectious DiseasesBMC series ¿ open, inclusive and trusted201111:133

DOI: 10.1186/1471-2334-11-133

Received: 22 January 2011

Accepted: 18 May 2011

Published: 18 May 2011

Abstract

Background

Super-infection in adult bacterial meningitis (ABM) is a condition wherein the cerebrospinal fluid (CSF) grows new pathogen(s) during the therapeutic course of meningitis. It is an uncommon but clinically important condition rarely examined in literature.

Methods

Twenty-seven episodes of super-infection states in 21 ABM patients collected in a 9.5-year study period (January 2001 to June 2010) were evaluated. The clinical characteristics, implicated pathogens, results of antimicrobial susceptibility tests, and therapeutic outcomes were analyzed.

Results

Twenty-one patients (13 men, 8 women) aged 25-73 years (median, 45 years) had post-neurosurgical state as the preceding event and nosocomial infection. The post-neurosurgical states included spontaneous intracranial hemorrhage (ICH) with craniectomy or craniotomy with extra-ventricular drainage (EVD) or ventriculo-peritoneal shunt (VPS) in 10 patients, traumatic ICH with craniectomy or craniotomy with EVD or VPS in 6 patients, hydrocephalus s/p VPS in 2 patients, and one patient each with cerebral infarct s/p craniectomy with EVD, meningeal metastasis s/p Omaya implant, and head injury. All 21 patients had EVD and/or VP shunt and/or Omaya implant during the whole course of ABM. Recurrent fever was the most common presentation and the implicated bacterial pathogens were protean, many of which were antibiotic resistant. Most patients required adjustment of antibiotics after the pathogens were identified but even with antimicrobial therapy, 33.3% (7/21) died. Morbidity was also high among survivors.

Conclusions

Super-infection in ABM is usually seen in patients with preceding neurosurgical event, especially insertion of an external drainage device. Repeat CSF culture is mandatory for diagnostic confirmation because most of the implicated bacterial strains are non-susceptible to common antibiotics used. Unusual pathogens like anaerobic bacteria and fungi may also appear. Despite antimicrobial therapy, prognosis remains poor.

Background

Super-infection in adult bacterial meningitis (ABM) is a condition in which the cerebrospinal fluid (CSF) grows new pathogen(s) during the therapeutic course of meningitis [1, 2]. This uncommon situation is rarely examined solely in overview studies of ABM [3, 4]. In ABM management, early and appropriate antibiotic use is an important strategy for better outcomes [57]. However, super-infection may cause a dilemma in antibiotic choice because starting a new antimicrobial regimen for this complicated condition during the therapeutic course of ABM is a difficult decision. To better delineate the clinical characteristics of super-infection in ABM, this study analyzed the clinical characteristics and therapeutic outcomes of ABM patients with super-infection.

Methods

The medical and microbiological records for CSF of all adult patients with bacterial meningitis admitted to Chang Gung Memorial Hospital (CGMH)-Kaohsiung, a 2482-bed acute-care teaching hospital and the largest tertiary care center in southern Taiwan, from January 2001 to June 2010 (9.5 years) were retrospectively reviewed. The hospital's Ethics Committee approved the study (IRB 99-1897C).

Diagnosis of ABM was based on: i) age ≥17 years; ii) positive CSF culture in patients with clinical presentation of acute meningitis (i.e. fever, altered consciousness, or seizure); and iii) at least one of the following CSF parameters: leukocyte count >0.25 × 109/L with predominant polymorphonuclear cells; CSF lactate concentration >3.5 mmol/L; glucose ratio (CSF glucose/serum glucose) <0.4; or CSF glucose concentration <2.5 mmol/L if no simultaneous blood glucose was determined [3, 4]. "Super-infection" in ABM was defined as a condition wherein CSF grew new pathogen(s) during the therapeutic course of an existing bacterial meningitis [1, 2].

For this study, ABM was classified as either nosocomial or community-acquired. Nosocomial meningitis was defined as positive bacterial infection not present on hospital admission, clinical evidence of infection no sooner than 48 hours after admission, or clinical evidence of meningitis within a short period of time, i.e. within one month after discharge from the hospital where the patient received an invasive procedure, especially a neurosurgical one. Otherwise, the patient was considered as having "community-acquired" infection.

Patients who developed meningitis related to head trauma with skull fractures or neurosurgical procedures were classified as "post-neurosurgical" meningitis. Otherwise, patients who demonstrated no clear distinctive disease characteristics and who had not undergone any invasive procedures were classified as "spontaneous" meningitis. "Mixed-infection" was defined as at least two bacterial organisms isolated concomitantly from CSF culture [4, 8].

During the study period, intravenous administration of vancomycin with either a 3rd - or 4th- generation cephalosporin (e.g. ceftriaxone, ceftazidime, or cefepime) were the initial empiric antibiotics used to treat adult patients with clinical evidence of bacterial meningitis. Further antibiotic adjustment was guided by results of pathogen identification and antibiotic susceptibility tests. Antibiotic susceptibility of the isolated pathogen was tested using the Kirby-Bauer diffusion method (BBL, Muller-Hinton II agars; Becton Dickinson Microbiology Systems, Cockeysville, MD) while bacterial susceptibility to antimicrobial agents was determined according to criteria of the National Committee for Clinical Laboratory Standards (CLSI). The therapeutic results were evaluated by using Glasgow Outcome Scale (GOS) [9]: score 1 = death, score 2 = persistent vegetative state, score 3 = severe disability, score 4 = moderate disability, score 5 = good recovery. Scores of 1-3 were classified as "poor prognosis" while scores of 4 and 5 were "good prognosis".

For comparative analysis, the patients were divided into fatal and non-fatal groups. Data such as sex, type of infection, underlying conditions, and clinical manifestations between these two patient groups were analyzed by Fisher's exact test. Age between the two groups was analyzed by Mann-Whitney U test.

Results

During the study period, 21 ABM patients aged 25-73 years (median 45 years), including 13 men and 8 women, had super-infection. Their basic clinical and laboratory data are listed in Tables 1 and 2. All had post-neurosurgical state as the preceding event and had contracted the infection nosocomially. The post-neurosurgical states included spontaneous intracranial hemorrhage (ICH) with craniectomy or craniotomy with extra-ventricular drainage (EVD) or ventriculo-peritoneal shunt (VPS) in 10 patients (Cases 2-4, 9-11, 14, 17, 20, 21), traumatic ICH with craniectomy or craniotomy with EVD or VPS in 6 patients (Cases 5, 6, 12, 13, 16, 18), hydrocephalus s/p VPS in 2 patients (Cases 7, 15), cerebral infarct s/p craniectomy with EVD in Case 1, meningeal metastasis s/p Omaya implant in Case 8, and head injury in Case 19. All 21 patients had undergone EVD and/or VPS and/or Omaya implant during the whole clinical course of ABM. The underlying medical conditions included diabetes mellitus in 3 patients (Cases 3, 10, 20), lung cancer in Case 8, brain tumor in Case 11, and liver cirrhosis in Case 21.
Table 1

Clinical data and implicated pathogens in the super-infections of the study patients with adult bacterial meningitis

Case

Gender

Age (years)

Underlying condition

Initial pathogen(s)

Antibiotics

Management

Interval* (days)

New presentation

New pathogen(s)

Antibiotics

Management

Survived

More than 7 days interval*

        
 

Gram (+) → G (-) or G (-) → G (+)

        

1

M

55

Infarct, craniectomy, EVD

Staphylococcus aureus §

LZD+EPM

Removed EVD → new EVDs

61

Fever, leukocytosis, CSF pleocytosis

ESBL-Escherichia coli

MEP

Removed EVD

No

2

F

48

SICH, craniectomy, EVD

Staphylococcus aureus §

VA+CAZ

Removed EVD → craniotomy, new EVDs

34

Fever, hydrocephalus

Stenotrophomonas maltophilia #

MOX+TMP+ TIG+ ATM

Removed EVD → New EVD → removed EVD → VP shunt

Yes

3

F

55

DM, SICH, craniotomy, VPS

Staphylococcus aureus §

VA

Removed VPS, debridement → new EVD

11

Fever, CSF pleocytosis

Acinetobacter baumannii

LZD+MEP

New EVD → ventriculo-pleural shunt

Yes

4

F

41

SICH, craniectomy, EVD

Staphylococcus epidermidis §

VA

Craniotomy, EVD → VPS

47

No

Enterobacter cloacae + Pseudomonas aeruginosa

CAZ

Removed VPS

No

5

M

73

TICH, craniectomy, EVD (removed)

Coagulase-negative staphylococci§

VA

New EVD

9

Fever, seizure, altered consciousness

Enterobacter cloacae

ROC

Removed EVD → VP shunt

Yes

6

M

46

TICH, craniectomy, VPS

Coagulase-negative staphylococci§

VA

Externalisation VPS → removed VPS → new EVDs

46

Fever

Coagulase-negative staphylococci§ + Acinetobacter baumannii

MEP

Removed EVD → new EVDs → VP shunt

Yes

7

M

34

Hydrocephalus, VPS

Staphylococcus epidermidis §

VA

Removed VPS, New EVDs

28

Fever, CSF pleocytosis

Acinetobacter spp

CEF

Removed EVD → New EVD → removed → VPS

Yes

8

F

45

Lung cancer, meningeal metastasis, Omaya implant, infection

Coagulase-negative staphylococci§

VA

Debridement, removed Omaya implant

42

Fever

Acinetobacter spp

CAZ

 

Yes

9

F

48

Brain tumor, SICH, craniectomy

Pseudomonas aeruginosa

CEF

New EVD

14

No

Enterococcus spp

AMP+CEF

New EVD → Removed EVD

Yes

10

M

67

DM, SICH, VPS, craniotomy, EVD

Acinetobacter baumannii

MEP

Removed VPS, new EVDs

41

Fever

Staphylococcus aureus §

VA

Removed EVD

No

 

Gram (-) → G (-)

      

11A

M

45

Brain tumor, SICH, craniectomy, VPS

Serratia marcescens @

MEP

Removed VPS, new EVD

29

Fever, reduced CSF glucose

Stenotrophomonas maltophilia

MOX+TMP

Removed EVD → new EVD

Treated

11B

      

90

No

Candida glabrata

FLU+AMB

 

Treated

11C

      

48

Fever

Stenotrophomonas maltophilia #

TMP+TIG

 

No

12

M

25

TICH, craniectomy, EVD

Pseudomonas aeruginosa

CAZ

New EVDs

37

No

Pseudomonas aeruginosa + ESBL-Proteus mirabilis

MEP

Removed EVD

Yes

13

M

25

TICH, craniotomy, VPS

Pseudomonas putida

CAZ

Removed VPS, new EVD

23

Leukocytosis

Acinetobacter spp @

MEP+SBM

Removed EVD → New EVDs → VPS

Yes

14

M

64

SICH, VPS

Serratia marcescens

VA + MEP

Removed VPS → new EVD

8

Fever, altered consciousness, hydrocephalus

Acinetobacter baumannii @

MEP+SBM+ TIG+CST

Removed EVD → new EVDs → VP shunt

Yes

15A

F

71

Old meningitis, hydrocephalus, VPS

Morganella morganii

CAZ

Externalization VPS→ removed → new VPS

47

Fever

Proteus mirabilis @

MEP

Removed VPS

Treated

15B

      

40

Fever

Glucose non-fermenting bacilli@

MEP+SBM

Scalp debridement → VPS

Yes

16

M

31

TICH, craniotomy, EVD (removed)

Stenotrophomonas maltophilia

CAZ

New EVDs

60

Fever

Stenotrophomonas maltophilia + Pseudomonas aeruginosa

MEP+CIP

New EVDs → VPS → removed VPS → Omaya implant

Yes

 

Others

      

17

F

58

SICH, EVD

Staphylococcus epidermidis§+ Acinetobacter lwoffii

VA+ROC+ CM

Removed EVD, new EVD

28

No

Staphylococcus epidermidis§+ Pseudomonas aeruginosa

CAZ

Removed EVD → New EVD → VPS

Yes

18A

M

48

TICH, craniectomy, EVD (removed)

Escherichia coli

MEP

New EVDs → craniotomy

36

Scalp wound infection

Candida tropicalis

FLU

removed EVD, debridement

Treated

18B

      

9

No

Escherichia coli+ Acinetobacter bauamnnii+ Enterococcus faecalis

AMP

Debridement → new EVD

Treated

18C

      

11

Fever

Staphylococcus aureus§+ Acinetobacter baumannii

VA+IPM

Removed EVD, new EVD

Treated

18D

      

14

Fever

Stenotrophomonas maltophilia

CIP

Removed EVD, new EVD → removed

Yes

19

M

58

Head injury

Viridan streptococci

VA+ROC

 

8

Hydrocephalus, ventriculitis, CSF pleocytosis

Prevotella+ Veilonella+ Fusobacterium

VA+ROC+ MET

New EVD

No

Less than 7 days interval

      

20

F

64

DM, VHD, SICH, craniectomy, EVD

Escherichia coli+ Enterococcus faecalis

VA+CAZ

Removed EVD, New EVD

3

Fever, leukocytosis, CSF pleocytosis

Enterobacter cloacae # @

VA+CAZ

Removed EVD → VPS

No

21

M

49

Liver cirrhosis, SICH, craniectomy, EVD (removed)

Coagulase-negative staphylococci§

VA

New EVD

5

No

Enterobacter aerogenes

CEF

New EVDs

No

§Oxacillin-resistant; # change antibiogram during treatment; @ cephalosporin-resistant; *the time interval from the finding of previous pathogen(s) to the detection of the following new pathogen(s).

Abbreviations: M, male; F, female; EVD, external ventricular drainage; SICH, spontaneous intra-cranial hemorrhage; DM, diabetes mellitus; VPS, ventriculo-peritoneal shunt; TICH, traumatic intra-cranial hemorrhage; ESBL, extended spectrum β-lactamase; LZD, linezolid; EPM, entrapenem; VA, vancomycin; CAZ, ceftazidime; CEF, cefepime; MEP, meropenem; ROC, ceftraixone; CM, chloroamphenicol; CSF, cerebrospinal fluid; MOX, moxifloxacin; TMP, trimethoprim-sulfamethoxazole; FLU, fluconazole; AMB, amphotericin B; TIG, tigecycline; SBM, sulbactam; ATM, aztreonam; CST, colistin; AMP, ampicillin; MET, metronidazole

There were 27 episodes of super-infection in the 21 ABM patients. The initial and subsequently implicated pathogens are listed in Table 1. Eight patients (Cases 1-8) were converted from Gram-positive (G(+)) pathogen infection to Gram-negative (G(-)) pathogen infection and two (Cases 9 and 10) were converted from G(-) pathogen to G(+) pathogen infection. Six patients (Cases 11-16) were converted from G(-) pathogen infections to another G(-) pathogen infection. Cases 17-21 had other converted states of implicated pathogens, while Case 18 had a more complicated conversion in different CSF cultures with different combinations of implicated pathogens noted in each culture.

Of the 27 episodes of super-infection, the time interval from finding the previous pathogen to detecting a new pathogen, i.e. appearance of super-infection, ranged from 3 to 90 days. Changes in clinical and laboratory evidence of super-infection were noted in 20 of the 27 episodes. Recurrent fever was the most common and found in 17 episodes (Cases 1-3, 5-8, 10, 11, 14-16, 18, 20), The other new presentations were CSF pleocytosis in 5 episodes (Cases 1, 3, 7, 19, 20), peripheral leukocytosis in 3 episodes (Cases 1, 13, 20), appearance of hydrocephalus in 3 episodes (Cases 2, 14, 19), altered consciousness in 2 episodes (Cases 5, 14), seizure in 1 episode (Case 5), scalp wound infection in 1 episode (Case 18) and appearance of ventriculitis in 1 episode (Case 19). The other 7 episodes without new clinical presentations were detected by regular CSF check-up studies.

Results of antibiotic susceptibilities of the implicated pathogens are listed in Table 2. Initial antibiotic use and the adjusted antibiotic after identification of the pathogens in the super-infections are listed in Table 1. The choices were guided by results of antimicrobial susceptibility tests. In addition to medical treatment, the other 20 patients except Case 8 had undergone removal of EVD or VPS and insertion of a new EVD or VPS.
Table 2

Antibiogram of implicated pathogens in the super-infections of the study patients with adult bacterial meningitis (n = 21)

Case

Pathogens

ROC

CAZ

MAX

MEP

CIP

TIG

TMP-SMX

AMP- SBM

1

ESBL-Escherichia coli

R

R

R

S

 

S

  

2

Stenotrophomonas maltophilia

    

S

 

R

 
      

R

 

R

 

3

Acinetobacter baumannii

 

I

S

S

R

  

S

   

S

S

R

R

  

S

4

Enterobacter cloacae

 

S

 

S

S

   
 

Pseudomonas aeruginosa

 

S

S

S

S

   

5

Enterobacter cloacae

S

S

 

S

S

   

6

Acinetobacter baumannii

 

S

S

S

S

   
   

I

S

S

S

   

7

Acinetobacter spp

I

S

S

S

S

  

S

8

Acinetobacter spp

S

S

S

S

S

  

S

9

Pseudomonas aeruginosa

 

S

S

S

S

   
   

R

S

S

    

10

Acinetobacter baumannii

 

S

S

S

S

   

11A

Serratia marcescens

I

R

R

S

    
 

Stenotrophomonas maltophilia

    

S

 

S

 

11C

Stenotrophomonas maltophilia

    

R

 

S

 

12

Pseudomonas aeruginosa

 

S

S

S

S

   
   

R

S

S

R

   
 

ESBL-Proteus mirabilis

R

R

S

S

R

   

13

Pseudomonas putida

 

S

S

R

S

   
 

Acinetobacter spp

R

R

R

I

R

S

 

I

14

Serratia marcescens

S

S

S

S

S

   
 

Acinetobacter baumannii

 

R

R

R

R

S

 

R

15A

Morganella morganii

R

S

S

S

S

   
 

Proteus mirabilis

R

R

R

S

R

   

15B

Glucose non-fermenting bacilli

R

R

R

R

I

   

16

Stenotrophomonas maltophilia

    

S

 

S

 
 

Pseudomonas aeruginosa

 

R

R

S

S

   

17

Acinetobacter lwoffii

 

S

 

S

S

   
 

Pseudomonas aeruginosa

 

S

 

S

S

   

18A

Escherichia coli

 

R

S

S

    

18B

Acinetobacter baumannii

 

R

I

S

R

  

R

18D

Stenotrophomonas maltophilia

    

S

   

19

Escherichia coli

S

S

S

S

    
 

Enterobacter cloacae

S

S

S

S

   

R

21

Enterobacter aerogenes

I

I

S

S

S

   
  

R

R

S

S

S

   

Abbreviations: ROC, ceftriaxone; CAZ, ceftazidime; MAX, cefepime; MEP, meropenem; CIP, ciprofloxacin; AMP-SBM, ampicillin-subactam; TIG, tigecycline; TMP-SMX, trimethoprime-sulfamethoxazole; LEV, levofloxacin; ESBL, extended spectrum β-lactamase; R, resistant; I, intermediate; S, susceptible

Note: ESBL-producing Escherichia coli was suspected by the disk-diffusion susceptibility test [10].

Non-Cephalosporin-susceptible Gram-negative bacteria (GNB) were used to describe isolates that were non-susceptible to ceftriaxone, ceftazidime, and cefepime. Intermediate and resistant isolates were considered non-susceptible [11]. Multi-drugs resistant (MDR) GNB was used to describe isolates that were non-susceptible to all antibiotics routinely tested including amikacin, (ampicillin-sulbactam in A. baumannii), ceftriaxone, ceftazidime, cefepime, ciprofloxacin, imepenem, and meropenem [12, 13]. The antimicrobial susceptibilities TMP-SMX, ciprofloxacin, levofloxacin, and moxifloaxcin of the Stenotrophomonas maltophilia strains isolated from the cerebrospinal fluid were determined concomitantly by the broth dilution method as described in the Clinical and Laboratory Standards (CLSI) guidelines.

With medical treatment, 14 patients survived while 7 died. Four of the 14 survivors (Cases 2, 6, 7, and 15) had clear consciousness while the other 10 had disturbed consciousness. One of the four survivors with clear consciousness (Case 7) had full recovery while the other three had quadriparesis. With GOS assessment, Case 7 had good prognosis, while the other 20 had poor prognosis. Comparative results between the fatal and non-fatal groups showed no significant clinical factors (Table 3).
Table 3

Clinical comparison between the fatal and non-fatal groups of the 21 adult bacterial meningitis patients with super-infection

Factors

Non-fatal

Fatal

P

 

(n = 14)

(n = 7)

 

Age, median (range)

48 (25 - 73)

55 (41 - 67)

0.400

Gender

   

   Male

8

5

0.656

   Female

6

2

 

Diabetes mellitus

   

   Yes

1

2

0.247

   No

13

5

 

Presence of new symptoms

   

   Yes

10

5

1.000

   No

4

2

 

Fever

   

   Yes

10

4

0.638

   No

4

3

 

Group

   

   G(+) > G (-) or G(+) > G(+)

7

3

1.000

   G(-) → G (-)

5

1

 

Intracranial hemorrhage (ICH)

   

   Spontaneous ICH

4

4

0.085

   Traumatic ICH

6

0

 

Abbreviation: G(+), Gram-positive pathogen; G(-), Gram-negative pathogen

Discussion

There is an increasing number of ABM patients with preceding neurosurgical condition, according to previous epidemiologic studies [4, 1416]. A preceding neurosurgical state is associated with mixed, relapsing, or recurrent infectious state of ABM [3, 4, 8]. In the current study, all 21 ABM patients with super-infection had a neurosurgical condition as the preceding event and all had undergone a procedure involving the insertion of a neurosurgical device during the entire clinical course. This may imply that neurosurgical device insertion is an important event in the development of super-infection. Aside from this pre-condition, 69% (18/26) of the super-infection episodes occurred despite an antibiotic-treatment course for bacterial meningitis longer than two weeks (Table 1). Thus, the occurrence of super-infection during ABM treatment may also suggest an inadequate infectious control program of the hospital.

Due to the preceding neurosurgical condition and existing bacterial meningitis, the clinical presentation of super-infection in ABM may be obscured. In the 27 episodes of the 21 ABM patients in this study, new evidence of meningitis is noted in 74.1% (20/27). Recurrence of fever was the most common, occurring in 63.0% (17/27) of the episodes. Other new evidences of meningeal infection included CSF pleocytosis, peripheral leukocytosis, and altered consciousness. All of these presentations are not unique and can be found in other infectious states, including central nervous system infections [6]. Therefore, a high index of suspicion is important because thus far, only repeat CSF follow-up studies and bacterial culture are the most important steps to confirm the diagnosis of ABM with super-infection.

Staphylococcal species were the most common G(+) pathogens implicated in both initial ABM and ABM with super-infection in the 21 study patients (Table 1). This finding is consistent with previous reports [1719] that have shown the high prevalence of staphylococcal infection in this specific group of patients. Most of the implicated staphylococcal pathogens shown in this study were methicillin-resistant. However, the presence of these resistant G(+) strains is not a therapeutic problem because intravenous vancomycin is one of the empiric antibiotics for ABM treatment in the hospital [4, 16].

It is known that early and appropriate antimicrobial use is of strategic importance in managing ABM [4, 5, 7]. Early diagnosis of super-infection in the therapeutic course is also important because most patients need an adjustment of antimicrobial agents after identification of the newly-implicated pathogens (Table 1). Such adjustments are important in Cases 1-10 because of the conversion from G(+) to G(-) bacterial pathogens in Cases 1-8 and from G(-) to G(+) pathogens in Cases 9 and 10.

Another important therapeutic consideration in antibiotic use is the emergence of multi-drug resistant bacterial strains in G(-) ABM [1113, 2025]. This problem is notable especially in patients with underlying G(-) ABM and a super-infection caused by another G(-) pathogen. Case 12 had ESBL-Proteus mirabilis infection, Cases 13 and 14 had multi-drug resistant (MDR) Acinetobacter spp. infections, and Case 16 had ceftazidime- and cefepime-resistant Pseudomonas aeruginosa infection. All four cases needed antibiotic adjustments for the corresponding newly-cultured bacterial pathogens. The emergence of Stenotrophomonas maltophilia as the implicated pathogen was noted in Cases 2, 11, and 18. Its emergence has caused a therapeutic challenge because it is usually not susceptible to traditional antibiotics used in ABM treatment [24, 25]. Presently, trimethoprime-sulfamethoxazole or quinolones are the antimicrobial agents of choice [23, 24].

In this study, another observed problem is the change of antibiotic susceptibilities during the therapeutic course of super-infection by G(-) pathogens (Table 2). MDR Stenotrophomonas maltophilia-strain emerged in Case 2 and meropenem-resistant A. Baumannii strain in Case 3. Other resistant strains that emerged during the therapeutic course of super-infection were ceftazidime-resistant A. baumannii in Case 6, ceftazidime-resistant Pseudomonas aeruginosa in Cases 9 and 12, and ceftazidime-resistant Enterobacter cloacae in Case 20. All of these changes in antibiotic susceptibilities required an adjustment of antimicrobial agents. In the super-infection of Case 18, anaerobic pathogens appeared and metronidazole was administered thereafter.

The appearance of anaerobic pathogens may also pose a therapeutic challenge because metronidazole is not a regular antimicrobial agent used in ABM treatment [37]. Other complicated super-infections in ABM were noted in Cases 11 and 18, in which Candida spp was the implicated pathogen. This uncommon super-infection was also noted in the report of Gelfand et al. [2]. Chronic use of broad spectrum antimicrobial agents is an important factor known to encourage the colonization of Candida organisms. Antifungal agents should be used for such an uncommon super-infection in treating ABM.

With an effort of management, the therapeutic result of super-infection ABM showed that 95.2% (20/21) of the involved patients belonged to the poor prognosis group. The mortality rate of this specific group of ABM patients is high (33.3%, 7/21) and survivors also have a high incidence of severe morbidity. Because most patients with super-infection ABM have both a preceding neurosurgical event and a pre-existing bacterial meningitis, it is difficult to assess the therapeutic outcome of this uncommon infectious state.

Conclusions

Super-infection in ABM is usually seen in patients with preceding neurosurgical event, including insertion of an external ventricular drainage device. Fever recurrence is the most common presentation and most new evidences are non-specific. Repeat CSF culture study is needed for diagnostic confirmation. The occurrence of super-infection in ABM has a great impact on the ABM treatment because a high percentage of the implicated bacteria strains are non-susceptible to common antibiotics used and early detection is important for adjusting the antibiotic regimen. Infections by unusual pathogens like anaerobes and fungi may appear and these deserve special attention because the choice of antimicrobials will be different. Because the pre-existing neurosurgical condition is complicated by super-infection, prognosis of super-infection in ABM remains poor. The interpretation of clinical data shown in this study is limited by its small case series and the retrospective data collection in a single hospital-based study. Further large-scale study is needed for better delineation of the presentation and prognosis.

Declarations

Acknowledgements

None of the authors are founded in this study.

Authors’ Affiliations

(1)
Department of Neurology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine
(2)
Department of Biological Science, National Sun Yat-Sen University
(3)
Neurosurgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine
(4)
Diagnostic Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine

References

  1. Finland M, Barnes MW: Acute bacterial meningitis at Boston City Hospital during 12 selected years, 1935-1972. J Infect Dis. 1977, 136: 400-415. 10.1093/infdis/136.3.400.View ArticlePubMed
  2. Gelfand MS, McGee ZA, Kaiser AB, Tally FP, Moses J: Candidal meningitis following bacterial meningitis. South Med J. 1990, 83: 567-570.View ArticlePubMed
  3. Durand ML, Calderwood SB, Weber DJ, Miller SL, Southwick FS, Caviness VS, Swartz MN: Acute bacterial meningitis in adults: a review of 493 episodes. N Engl J Med. 1993, 328: 21-28. 10.1056/NEJM199301073280104.View ArticlePubMed
  4. Chang WN, Lu CH, Huang CR, Tsai NW, Chuang YC, Chang CC, Chen SF, Chien CC: Changing epidemiology of adult bacterial meningitis in southern Taiwan: a hospital-based study. Infection. 2008, 36: 15-22. 10.1007/s15010-007-7009-8.View ArticlePubMed
  5. Chaudhurl A, Martinez-Martin P, Kennedy PG, Andrew Seaton R, Portegies P, Bojar M, Steiner I, EFNS Task Force: EFNS guidelines on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Eur J Neurol. 2008, 15: 649-659. 10.1111/j.1468-1331.2008.02193.x.View Article
  6. Ziai WC, Lewin JJ: Update in the diagnosis and management of central nervous system infections. Neurol Clin North Am. 2008, 26: 427-468.View Article
  7. Fitch MT, van de Beek D: Emergency diagnosis and treatment of adult meningitis. Lancet Infect Dis. 2007, 7: 191-200. 10.1016/S1473-3099(07)70050-6.View ArticlePubMed
  8. Chang WN, Lu CH, Huang CR, Chuang YC: Mixed infection in adult bacterial meningitis. Infection. 2000, 28: 8-12. 10.1007/s150100050003.View ArticlePubMed
  9. Jannett B, Bond M: Assessment of outcome after severe brain damage. Lancet. 1975, 1 (7905): 480-484.View Article
  10. Hsieh CJ, Shen YH, Hwang KP: Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum β-lactamase (ESBL) and non-ESBL producing Escherichia coli. J Microbiol Immunol Infect. 2010, 43: 240-248. 10.1016/S1684-1182(10)60038-2.View ArticlePubMed
  11. Chang CJ, Ye JJ, Yang CC, Huang PY, Chiang PC, Lee MH: Influence of third-generation cephalosporin resistance on adult in-hospital mortality from post-neurosurgical bacterial meningitis. J Microbiol Immunol Infect. 2010, 43: 301-309. 10.1016/S1684-1182(10)60047-3.View ArticlePubMed
  12. Pena C, Suarez C, Tubau F, Juan C, Moya B, Dominguez MA, Oliver A, Pujol M, Ariza J: Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain over-expression MexXY-OprM and producing an integron-borne PSE-1 beta-lactamase. J Clin Microbiol. 2009, 47: 2381-2387. 10.1128/JCM.00094-09.PubMed CentralView ArticlePubMed
  13. Chen SF, Chang WN, Lu CH, Chuang YC, Tsai HH, Tsai NW, Chang WN, Lee PY, Chien CC, Huang CR: Adult Acinetobacter meningitis and its comparison with non-Acinetobacter bacterial meningitis. Acta Neurol Taiwan. 2005, 14: 125-129.
  14. Lu CH, Chang WN, Chang HW: Adult bacterial meningitis in southern Taiwan: epidemiologic trend and prognostic factors. J Neurol Sci. 2000, 182: 36-44. 10.1016/S0022-510X(00)00445-7.View ArticlePubMed
  15. Kim BN, Pelep AY, Lodise TP, Lipman J, Li J, Nation R, Paterson DL: Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009, 9: 245-255. 10.1016/S1473-3099(09)70055-6.PubMed CentralView ArticlePubMed
  16. Chang WN, Lu CR, Huang CR, Chuang YC, Tsai NW, Chen SF, Chang CC, Wang HC, Chien CC, WU JJ: Epidemiology of adult staphylococcal meningitis in southern Taiwan: a clinical comparison of Staphylococcus aureus infection with coagulase-negative staphylococcal infection. Jpn J Infect Dis. 2007, 60: 262-266.PubMed
  17. Chang WN, Lu CH, Wu JJ, Chang HW, Tsai YC, Chen FT, Chien CC: Staphylococcus aureus meningitis in adults: a clinical comparison of infections caused by methicillin-resistant and methicillin-sensitive strains. Infection. 2001, 29: 245-250. 10.1007/s15010-001-1092-z.View ArticlePubMed
  18. Huang CR, Lu CH, Wu JJ, Chang HW, Chien CC, Lei CB, Chang WN: Coagulase-negative staphylococcal meningitis: clinical characteristics and therapeutic outcomes. Infection. 2005, 33: 56-60. 10.1007/s15010-005-4083-7.View ArticlePubMed
  19. Tsai MH, Lu CH, Huang CR, Chuang YC, Tsai NW, Tsai HH, Chen SF, Li CS, Chang HW, Chien CC, Chang WN: Bacterial meningitis in young adults in southern Taiwan: clinical characteristics and therapeutic outcomes. Infection. 2006, 34: 2-8. 10.1007/s15010-006-4144-6.View ArticlePubMed
  20. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, Luh KT: Pan drug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis. 2002, 8: 827-832.PubMed CentralView ArticlePubMed
  21. Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, Paterson DL: Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect. 2009, 9: 245-255. 10.1016/S1473-3099(09)70055-6.View Article
  22. Huang CR, Lu CH, Chuang YC, Tsai NW, Chang CC, Chen SF, Wang HC, Chien CC, Chang WN: Adult Pseudomonas aeruginosa meningitis: high incidence of underlying medical and/or post-neurosurgical conditions and high mortality rate. Jpn J Infect Dis. 2007, 60: 397-399.PubMed
  23. Huang CR, Lu CH, Chang WN: Adult Enterobacter meningitis: a high incidence of co-infection with other pathogens and frequent association with neurosurgical procedures. Infection. 2001, 29: 75-79. 10.1007/s15010-001-0087-0.View ArticlePubMed
  24. Looney WJ, Narita M, Mühlemann K: Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009, 9: 312-323. 10.1016/S1473-3099(09)70083-0.View ArticlePubMed
  25. Nicodemo AC, Garcia Paez JI: Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007, 26: 229-237. 10.1007/s10096-007-0279-3.View ArticlePubMed
  26. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2334/​11/​133/​prepub

Copyright

© Huang et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.